Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cell2in-MS
- Development stage
- Preclinical
- Lead developer
- Cell2in
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
Cell2in-MS is a preclinical mesenchymal stem cell (MSC)-based therapy developed by Cell2in for the treatment of multiple sclerosis (MS). The therapy utilizes the proprietary FreSHtracer™ technology to identify and select MSCs with high levels of intracellular glutathione (GSH), which serves as a biomarker for enhanced stem cell potency and function. By enriching for these high-quality cells, the therapy aims to modulate oxidative stress and inflammation in the central nervous system through the Nrf2 pathway and increased glutathione production. This approach is designed to mitigate myelin damage and promote tissue repair in MS patients.
02
Targets
GSH (Glutathione synthesis / redox)
Beyond the preview
Go deeper on Cell2in-MS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cell2in-MS.